Activated Cell Therapy, Incorporated is a recently formed biotechnology company committed to the development and application of cell based therapeutics, including immunotherapeutic approaches to HIV infection. The company has in-house expertise in cellular immunology, molecular genetics, cell processing and large-scale cell expansion. We will be utilizing this expertise in the proposed SPIRAT for purposes of producing and expanding HIV antigen specific cytolytic T cell clones for adoptive immunotherapy. These clones will be generated from HIV-seronegative donors with technology developed by our collaborators at Stanford University (Project II). We will expand and process these cells under good manufacturing practices for purposes of assessing their anti-viral effects, in vivo, in pilot clinical studies as described in Project I. In addition, we will make use of a highly sensitive technique to determine homing and half-life of donor T cells in the peripheral blood and tissues of the recipient. This technique is based on the highly polymorphic VNTR markers which will allow us to distinguish donor and recipient cells in a quantitative manner. Finally, where applicable we will transduce the CTL clones with a TAR decoy vector to protect the CTL from HIV infection post-infusion. By carefully defining the specificity, potency, and clonality of our expanded HIV specific CTL clones, we should be able to gain significant insight into their impact on viral load and clinical course.

Project Start
1997-06-01
Project End
1999-12-31
Budget Start
Budget End
Support Year
4
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
Shapero, M H; Kundu, S K; Engleman, E et al. (2000) In vivo persistence of donor cells following adoptive transfer of allogeneic dendritic cells in HIV-infected patients. Cell Transplant 9:307-17
Peshwa, M V; Benike, C; Dupuis, M et al. (1998) Generation of primary peptide-specific CD8+ cytotoxic T-lymphocytes in vitro using allogeneic dendritic cells. Cell Transplant 7:1-9
Kundu, S K; Engleman, E; Benike, C et al. (1998) A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. AIDS Res Hum Retroviruses 14:551-60
Engleman, E G (1997) Dendritic cells: potential role in cancer therapy. Cytotechnology 25:1-8
Takamizawa, M; Rivas, A; Fagnoni, F et al. (1997) Dendritic cells that process and present nominal antigens to naive T lymphocytes are derived from CD2+ precursors. J Immunol 158:2134-42
Dupuis, M; Peshwa, M V; Benike, C et al. (1997) Allogeneic dendritic cell induction of HIV-specific cytotoxic T lymphocyte responses from T cells of HIV type 1-infected and uninfected individuals. AIDS Res Hum Retroviruses 13:33-9
Mehta-Damani, A; Markowicz, S; Engleman, E G (1995) Generation of antigen-specific CD4+ T cell lines from naive precursors. Eur J Immunol 25:1206-11
Fagnoni, F F; Takamizawa, M; Godfrey, W R et al. (1995) Role of B70/B7-2 in CD4+ T-cell immune responses induced by dendritic cells. Immunology 85:467-74